Biohaven's BHV-1530 cancer drug selected for ENA 2026 presentation
Biohaven announced that its cancer drug BHV-1530, an FGFR3-directed antibody-drug conjugate, has been selected for an oral presentation at the ENA 2026 conference in November 2026. Early Phase 1 clinical data showed confirmed partial responses in heavily pretreated patients with advanced solid tumors, with no dose-limiting toxicities. The company has also entered a clinical supply agreement with Regeneron Pharmaceuticals to evaluate BHV-1530 in combination with cemiplimab.
Biohaven’s cancer drug data selected for presentation at symposium
Biohaven Ltd. (NYSE:BHVN) announced that Phase 1 data for its antibody-drug conjugate, BHV-1530, targeting FGFR3, will be presented at the 38th EORTC-NCI-AACR Symposium. The data from the ongoing BHV1530-101 study showed early clinical activity, including confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities. Biohaven has also partnered with Regeneron Pharmaceuticals, Inc. to evaluate BHV-1530 in combination with cemiplimab for solid tumors.
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. announced that clinical data for its novel FGFR3-directed antibody-drug conjugate (ADC) BHV-1530, which utilizes a proprietary TopoIx payload, has been selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium in November 2026. The Phase 1 findings demonstrate early clinical activity and a differentiated, tolerable safety profile, with confirmed partial responses observed in heavily pretreated patients. Biohaven has also initiated enrollment for a combination study of BHV-1530 with cemiplimab (Libtayo) under a clinical supply agreement with Regeneron Pharmaceuticals.
Biohaven Presents BHV-1530 Phase 1 Study Findings at EORTC-NCI-AACR Symposium
Biohaven is presenting Phase 1 study findings for its drug BHV-1530 at the EORTC-NCI-AACR Symposium, highlighting early clinical activity and a favorable safety profile in heavily pretreated cancer patients. The company has also partnered with Regeneron to study BHV-1530 in combination with cemiplimab, aiming to enhance antitumor immune responses. BHV-1530 is the first FGFR3-targeted ADC, designed to address FGFR3-driven cancers, with ongoing trials expected to provide new treatment options and strengthen Biohaven's market position.
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap
Biohaven (BHVN) has seen recent stock price movement, with a 4.41% 1-day return and a 12.50% 7-day return, despite ongoing losses and zero revenue. The company trades at a significant discount to its intrinsic value estimate of $70.05 per share according to a DCF model, but its price-to-book ratio is very high compared to peers, highlighting a mixed valuation picture. Investors are weighing the pipeline potential against substantial execution and funding risks, including a short cash runway and recent shareholder dilution.
Biohaven (BHVN) discloses options tied to SVP's son
Biohaven Ltd. (BHVN) reported an indirect stock option grant of 1,000 options to Kimberly Gentile, SVP of Clinical Operations, for her son's employment. The options have an exercise price of $12.34 per share and expire in 2036, with vesting occurring in four equal installments from 2026 to 2029, contingent on her son's continuous service. Gentile explicitly disclaims beneficial ownership of these securities.
Biohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA Requires Every Sponsor to Answer
The FDA issued a partial clinical hold on Biohaven's BHV-7000 epilepsy studies due to insufficient preclinical data on a specific metabolite identified in rodent studies. This action, which halted new patient enrollment, highlights Biohaven's failure to address fundamental pharmacology questions about the drug's metabolic profile before advancing to pivotal trials, despite FDA guidance requiring such characterization prior to substantial human exposure. The hold underscores broader issues in preclinical due diligence and regulatory compliance within the pharmaceutical industry, potentially delaying the drug's pivotal readout for six to twelve months.
Biohaven Faces New Securities Investigation
Biohaven Ltd. is under a new securities investigation by Levi & Korsinsky LLP after its shares dropped nearly 15% following a partial FDA clinical hold on its experimental epilepsy treatment, BHV-7000. This new inquiry is distinct from an existing federal securities class action filed in 2025, which also involves Biohaven. The investigation will examine Biohaven's disclosures surrounding the FDA action and the timing of its public statements regarding the drug's safety and efficacy.
Biohaven’s epilepsy drug hit with FDA clinical hold
The FDA has placed a partial clinical hold on Biohaven's epilepsy drug opakalim due to safety concerns over a metabolite identified in nonclinical testing. While new patient enrollment is paused for pivotal trials, existing patients can continue receiving the drug. This setback comes shortly after SK Biopharmaceuticals acquired global rights to opakalim, which had previously failed trials for other conditions.
Biohaven faces partial FDA hold on BHV-7000 program
Biohaven Ltd. (BHVN) received a partial clinical hold from the FDA on its BHV-7000 program due to concerns over a rodent-identified metabolite, pausing new patient enrollment in its Phase 3 trials for refractory focal epilepsy. Despite this, dosing for already randomized patients and the timeline for the BHV7000-303 study remain unaffected. Biohaven recently licensed its Kv7 ion channel platform, including BHV-7000, to SK Biopharmaceuticals, highlighting its continued commitment to the epilepsy franchise.
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
The FDA has placed a partial clinical hold on Biohaven's focal epilepsy drug, BHV-7000 (opakali), pausing enrollment in two late-stage trials due to concerns surrounding a metabolite identified during rodent testing. This news caused Biohaven's stock to fall over 13% and marks the second regulatory setback for the company in a year. While dosing continues for existing participants, the hold is expected to delay the readout of the RISE 2 trial, which will likely need positive results for regulatory approval.
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
Biohaven Ltd. shares dropped 17% after the FDA issued a partial clinical hold on new patient enrollment for its BHV-7000 trials. The hold was prompted by concerns over a specific metabolite found in rodent testing, requiring additional nonclinical studies. Despite the hold, existing patients will continue treatment, and the company expects to provide further data in the coming weeks.
Biohaven Pharma stock falls after RBC Capital downgrade
Biohaven Pharmaceutical Holding Co Ltd (BHVN) shares dropped 4.2% after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered its price target to $19 from $23. The downgrade was attributed to the stock's approximately 100% gain since earlier this year, a strengthened balance sheet from a recent Kv7 program deal, and a higher risk profile with fewer major catalysts expected in the next 12 months. Analyst Leonid Timashev noted concerns about limited patient data, less validated mechanisms, and regulatory questions surrounding the company's programs.
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Biohaven has sold the rights to its most advanced experimental drug, opakalim, for epilepsy to SK Biopharmaceuticals in a deal potentially worth up to $795 million plus royalties. This transaction provides Biohaven with immediate funds and reduces development risk, though it means foregoing the full "upside" of a potential blockbuster drug. The move comes as Biohaven, a company that previously sold its migraine drug to Pfizer, has faced several research and regulatory setbacks with other pipeline assets.
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
Biohaven Ltd. (BHVN) shares surged 13% after licensing its experimental epilepsy drug, opakalim, to SK Biopharmaceuticals in a deal potentially worth $795 million plus royalties. The agreement provides Biohaven with $400 million in non-dilutive capital, extending its cash runway through 2028 and allowing it to focus on other pipeline drugs, including its obesity and Graves' disease programs. Retail investors are optimistic, with particular anticipation for mid-stage obesity data expected in late 2026.
Biohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal
Biohaven's shares rose 7% after announcing a global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform and epilepsy candidate opakalim. The deal could bring Biohaven up to $795 million in upfront and milestone payments, including $400 million in cash, and ongoing royalties. SK Biopharmaceuticals will take over future program costs and regulatory responsibilities for opakalim, which is currently in late-stage development for focal epilepsy.
Biohaven, Yale win $4M judgment in trade secret case By Investing.com
Biohaven Ltd. and Yale University have been awarded a combined $4 million judgment in a trade secret misappropriation and breach of contract lawsuit against Avilar Therapeutics, Inc. and RA Capital Management GP, LLC. The judgment follows a jury verdict which found that RA Capital and Avilar willfully and maliciously misappropriated Yale's MODA targeted protein degradation platform trade secret and that RA Capital breached a 2019 confidentiality agreement with Yale. Yale received $2 million for the breach of contract and $1 million each from both Biohaven and Yale for trade secret misappropriation.
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
A U.S. District Court in Delaware has formalized a $4 million award to Biohaven Ltd. and Yale University, ruling that RA Capital Management GP, LLC and Avilar Therapeutics, Inc. willfully and maliciously misappropriated a trade secret related to Yale's "MODA" protein degradation platform. The judgment confirms a jury's verdict, with $2 million awarded to Yale for RA Capital's breach of contract and $1 million each to Yale and Biohaven for trade secret misappropriation. Biohaven had licensed the MODA platform from Yale and pursued litigation after RA Capital allegedly used confidential information to establish a competing company, Avilar, rather than partnering with Yale.
Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?
Biohaven (BHVN) reported improved Q2 2026 earnings, reducing its net loss to US$137.31 million. While the stock's price-to-book ratio of 171.2x suggests overvaluation compared to industry averages, a Discounted Cash Flow (DCF) model from Simply Wall St indicates the shares might be significantly undervalued at $13.85, estimating a future cash flow value of $53.83 per share. The article highlights the conflicting valuation perspectives, urging investors to consider both the risks of a loss-making biotech and the potential of its pipeline.
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses
Biohaven Ltd. (BHVN) reported narrower net losses in Q2 and H1 2026, with a Q2 net loss of US$137.31 million and an H1 net loss of US$267.84 million. Despite these reduced losses, the company's shares declined by 9.09% over seven days, as investors remain concerned about its high cash burn, reliance on future capital raises, and whether its deep pipeline can justify persistent heavy spending. The investment narrative continues to hinge on upcoming pivotal data for its epilepsy and Graves' disease treatments.
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses
Biohaven Ltd. (BHVN) reported narrower net losses for Q2 and H1 2026, with a Q2 net loss of US$137.31 million and an H1 net loss of US$267.84 million, both improvements over the previous year. Despite the reduced losses, the company remains unprofitable, and its shares experienced a 9.09% decline over seven days. The investment narrative continues to focus on its pipeline in epilepsy and autoimmune disease, with upcoming data releases being key catalysts, though concerns about cash burn and future capital raises persist.
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses
Biohaven Ltd. reported narrower net losses for Q2 and H1 2026, with Q2 losses at US$137.31 million and H1 losses at US$267.84 million. Despite this, the company's shares dropped 9.1%, and concerns remain regarding its cash burn, reliance on future capital raises, and whether its significant pipeline can justify current spending. Investors are advised to consider various perspectives and the company's financial health before making investment decisions.
Price to earnings forward of Biohaven Ltd. – NYSE:BHVN
This article provides financial information for Biohaven Ltd. (NYSE: BHVN), specifically focusing on its forward price-to-earnings ratio. The content appears to be a page from a financial data platform, displaying the company's ticker, exchange, and a placeholder for the "Price to earnings forward" value.
HC Wainwright Decreases Earnings Estimates for Biohaven
HC Wainwright has lowered its FY2030 earnings per share estimate for Biohaven (NYSE:BHVN) to $1.84 from $2.12, maintaining a Neutral rating and a $10 price target. This revision comes after Biohaven reported a quarterly loss of $0.91 per share, missing consensus estimates. Despite this, Biohaven holds a "Moderate Buy" consensus rating from other analysts, with an average target price of $21.75, and institutional investors own a significant portion of the company's shares.
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN
NewEdge Wealth LLC has initiated a new position in Biohaven Ltd. (NYSE:BHVN), acquiring 245,670 shares valued at approximately $3.66 million during the second quarter. This investment represents about 0.16% of Biohaven's stock. Other institutional investors have also adjusted their holdings in Biohaven, while analysts have issued a range of ratings, with a consensus of "Moderate Buy" and a target price of $21.75.
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages
Biohaven Ltd. (NYSE:BHVN) has received a "Moderate Buy" consensus rating from seventeen research firms, with an average 12-month price target of $21.75. The company's shares opened at $13.59, and it recently reported a quarterly EPS of negative $0.91, missing the consensus estimate. Institutional investors hold 88.78% of the stock, and analysts anticipate a full-year loss of approximately $3.11 per share.
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Biohaven Ltd. (BHVN) by 190% in the first quarter, bringing its total to 121,554 shares. Several other institutional investors also expanded their positions, contributing to the high institutional ownership of 88.78%. Despite a reported quarterly loss of $0.91 per share, analysts maintain a "Moderate Buy" rating with a consensus price target of $21.75, considerably higher than the stock's recent trading price.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million. The company also appointed AI-focused investor John Yetimoglu to its Board, signaling a push to integrate advanced computation into R&D. Despite these developments, the article emphasizes that Biohaven's investment narrative still heavily relies on the success of its epilepsy and MoDE degrader programs, given its zero revenue and short cash runway.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) is gaining attention due to an expanded oncology collaboration with Regeneron Pharmaceuticals, though its long-term shareholder returns have been weak. A Simply Wall St discounted cash flow (DCF) model estimates a fair value of $54.53, suggesting the stock is significantly undervalued compared to its current price of $14.64, despite ongoing losses and high valuation risks based on its P/B ratio. Investors are advised to examine underlying data and warnings signs before making decisions.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) has expanded its oncology collaboration with Regeneron Pharmaceuticals, leading to recent stock momentum despite a longer history of weak returns and losses. Simply Wall St's Discounted Cash Flow (DCF) model estimates BHVN to be 73% undervalued with a fair value of $54.53 against its current trading price of $14.64, based on assumptions of future revenue and cash generation. However, the company faces significant clinical and regulatory hurdles, and its high Price-to-Book ratio of 180.9x compared to an industry average of 2.5x suggests high valuation risk.
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands
Biohaven (BHVN) is gaining attention after expanding its oncology collaboration with Regeneron Pharmaceuticals. Despite a recent slight easing in share price, the stock shows strong 90-day returns, contrasting with weaker long-term performance. A discounted cash flow (DCF) model by Simply Wall St suggests Biohaven could be 73% undervalued, estimating a fair value of $54.53 against its current trading price of $14.64, although its high P/B ratio indicates significant valuation risk.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short cash runway, with investors needing to consider future funding and potential dilution. The article suggests that while the AI appointment aligns with Biohaven's data-driven R&D, it doesn't immediately alter the key value drivers of its epilepsy and MoDE degrader programs.
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven
Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund LP. The stake is based on Biohaven's 150,560,990 Common Shares outstanding as of April 30, 2026.
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN
Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, analysts maintain a "Moderate Buy" rating with an average price target of $21.75 for Biohaven.
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?
Biohaven Ltd. reported narrower losses in Q2 2026 and appointed an AI-focused investor to its board, signaling a push into advanced computation for R&D. Despite this, the company still faces significant financing risk due to ongoing heavy losses and a short cash runway, with pivotal trial readouts remaining key value drivers. Investors must consider future funding and potential dilution alongside the company's volatile stock price and differing fair value estimates.
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)
Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader analyst consensus for Biohaven Ltd. is a Moderate Buy with an average price target of $16.33.
Biohaven Pharma stock price target raised to $23 by RBC Capital
RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by 2035, and anticipates success in the near-term Kv7 readout. Despite some elevated spending and concerns about cash burn, the pipeline is deemed attractive, and the company is progressing with other trials like RISE3 for epilepsy and a Phase 3 trial for Graves’ disease.
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity
Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable securities, which management expects to fund operations for at least one year. Biohaven is focused on advancing its R&D portfolio across immunology, obesity, neuroscience, and oncology, including key clinical programs such as Kv7 ion channel modulation for epilepsy and Molecular Degrader of Extracellular Proteins (MoDE) for immunological diseases.
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an average price target of $21.62.
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company increased its stake in Biohaven Ltd. (NYSE:BHVN) by 52.5% in Q1, now owning 202,975 shares valued at $1.72 million. Other institutional investors also significantly increased their holdings, with hedge funds and institutional investors collectively owning 88.78% of the stock. Analysts currently rate Biohaven as a "Moderate Buy" with an average price target of $21.62.
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending
Biohaven Ltd. has filed its Q2 2026 financial report, revealing continued operating losses but also a reduction in research and development spending compared to the previous year. This report covers the three- and six-month periods ending June 30, 2026. The full details are available via an SEC Form 10-Q filing.
Biohaven earnings set to show cash burn ahead of epilepsy data
Biohaven Pharmaceutical Holding Co Ltd is expected to report its second-quarter earnings, with analysts forecasting a narrower loss of 75 cents per share. Investors will be closely watching the company's cash burn rate and updates on its epilepsy drug candidate, opakalim, which has topline results expected in the second half of 2026. The stock faces skepticism from some analysts due to competitive concerns and cash runway, while others maintain a positive outlook.
Understanding Momentum Shifts in (BHVN)
This article analyzes Biohaven Ltd. (BHVN) stock, highlighting a potential shift where strong near-term sentiment might challenge persistent mid and long-term weakness. It identifies resistance testing and outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis emphasizes risk-reward scenarios and multi-timeframe signal insights.
Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026
Biohaven Ltd. has announced the appointment of John Yetimoglu to its Board of Directors and as a member of the Nominating and Governance Committee, effective August 6, 2026. Mr. Yetimoglu, founder and CIO of Infinitum, brings expertise in semiconductors, videogaming, and AI application platforms. His appointment is expected to enhance the company's strategic oversight in leveraging AI and advanced computational methods for medical breakthroughs.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Ltd. (NYSE: BHVN) has appointed John Yetimoglu, founder and CIO of Infinitum and a board director at Groq, to its Board of Directors. Yetimoglu brings extensive experience in frontier AI and technology investing, which Biohaven anticipates will strengthen its strategic oversight as it integrates AI, machine learning, and advanced computational methods into drug discovery and development. This appointment highlights Biohaven's belief in the convergence of biology, data, and computation to drive future medical breakthroughs.
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed stock information for Biohaven Ltd. (BHVN), including its current stock price, historical data, key events, and financial metrics. The company, a biopharmaceutical firm, focuses on treatments for immunology, neuroscience, and oncology, with several drug candidates in various clinical trial phases. The page also offers analyst insights, performance comparisons against the S&P 500, and a list of similar biotechnology companies.
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide?
Biohaven (BHVN) recently appointed John Yetimoglu, an AI-focused investment leader, to its Board, signaling a stronger push into data-driven drug discovery. Despite recent stock volatility, a Discounted Cash Flow (DCF) model suggests Biohaven is significantly undervalued at $13.63, with a fair value estimate of $58.37 per share, driven by high future growth assumptions. However, its high Price-to-Book (P/B) ratio of 15.8x compared to industry averages and risks like limited cash runway and potential shareholder dilution present a mixed valuation picture.
Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances
Biohaven Ltd. (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors to bolster its artificial intelligence and computational technologies strategy in drug discovery and development. Yetimoglu, founder of Infinitum and an early investor in Groq, brings extensive experience in emerging technologies and AI infrastructure to the biopharmaceutical company. This appointment reflects a growing trend in the life sciences industry to integrate AI expertise at the board level to accelerate innovation and decision-making.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Ltd. has appointed technology investor John Yetimoglu to its Board of Directors. Yetimoglu, founder of Infinitum and a board director at Groq, brings expertise in frontier AI and technology investing. His appointment aims to strengthen Biohaven's strategic oversight as the company integrates AI and computational methods into its drug discovery and development processes.
Biohaven Pharma earnings on deck amid epilepsy trial scrutiny
Biohaven Pharmaceutical Holding Co. is set to report second-quarter results, with analysts anticipating a narrower loss per share. Investors will be closely watching for updates on the company's cash runway and the timeline for pivotal Phase 2/3 epilepsy trial results for its experimental drug, opakalim, especially given growing skepticism about its differentiation from rivals. The company's recent restructuring efforts and upcoming clinical data are crucial for its valuation.
